<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123564</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002AHU02T</org_study_id>
    <nct_id>NCT01123564</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion</brief_title>
  <acronym>BRAVO</acronym>
  <official_title>A Randomized, Controlled, Two-center Phase II Study Assessing the Efficacy and Safety of Intravitreal Lucentis Injections in Patients With Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Debrecen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess if Lucentis injection applied into the eye is superior to
      conventional treatment concerning the prevention of visual loss in patients having clinically
      significant macular edema secondary to retinal vein occlusion
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy compared to conventional treatment assessed by BCVA(best corrected visual acuity)</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the superiority of intravitreal (IVT) ranibizumab to conventional treatment concerning prevention of visual loss or improvement of BCVA as determined by the mean change of BCVA tested by ETDRS chart compared to baseline in 12 months period, when intravitreal ranibizumab is applied monthly in the first 3 months period, and later when visual acuity (VA) decreases with more than 5 letters at any visit performed monthly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by change in macular thickness</measure>
    <time_frame>12 months with monthly assessment</time_frame>
    <description>The efficacy of treatment concerning change of anatomical structure of macular region detected by Optical Coherence Tomography (OCT) - the mean change of macular thickness (micron) at each months of 1 year period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Lucentis (ranibizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits</description>
    <arm_group_label>Lucentis (ranibizumab)</arm_group_label>
    <other_name>Lucentis intravitreal injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Argon laser treatment</intervention_name>
    <description>Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.</description>
    <arm_group_label>Laser</arm_group_label>
    <other_name>Laser photocoagulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macular edema persisting for more than 3 months period despite conventional
             medication.

          -  Central retinal vein occlusion is confirmed by slit-lamp biomicroscopy and fluorescein
             angiography (FLAG).

          -  Patients randomized into ranibizumab-treated group do not receive macular laser
             treatment.

          -  Macular edema is defined by OCT: the thickness of central foveal area calculated by
             macular map analysis is above 280 μm and/or retinal thickness is above 330 μm at any
             region of the macula calculated by retinal thickness analysis.

          -  Baseline visual acuity is less than 64 ETDRS letters (or 0.4 decimal equivalent).

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Additional vitreoretinal diseases

          -  History of pars plana vitrectomy

          -  Previous macular grid laser treatment

          -  Intravitreal triamcinolone acetonid treatment

          -  Complicated cataract surgery

          -  Advanced glaucomatous damage of optic nerve head

          -  Cataract (except mild, defined as grade 1 nuclear sclerosis and/or grade 1 posterior
             subcapsular cataract)

          -  Age-related macular degeneration

          -  Pregnancy and lactation

          -  Women in childbearing potential who are not using double safe contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zsolt Balla, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pecs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zsolt Balla, MD</last_name>
    <phone>+3672536141</phone>
    <email>balla07@freemail.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Debrecen Medical and Health Science Center Dept of Ophthalmology</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attila Vajas, MD</last_name>
      <email>vajasa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Attila Vajas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pecs, Medical School, Department of Ophthalmology</name>
      <address>
        <city>Pecs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Balla, MD</last_name>
      <phone>+3672536141</phone>
      <email>balla07@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Zsolt Balla, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>May 13, 2010</last_update_submitted>
  <last_update_submitted_qc>May 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Zsolt Balla/assistant lecturer</name_title>
    <organization>University of Pecs, Medical Scool, Dept of Ophthalmology</organization>
  </responsible_party>
  <keyword>macular edema secondary to retinal vein occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

